Last reviewed 2026-04-23 · How we verify

Jiedu Huayu Oral Prescription

Beijing Tiantan Hospital · Phase 3 active Small molecule

Jiedu Huayu Oral Prescription is a Small molecule drug developed by Beijing Tiantan Hospital. It is currently in Phase 3 development for Hepatic fibrosis and cirrhosis (phase 3 development).

Jiedu Huayu Oral Prescription is a traditional Chinese medicine formulation designed to detoxify and resolve blood stasis, potentially improving hepatic fibrosis and cirrhosis outcomes.

Jiedu Huayu Oral Prescription is a traditional Chinese medicine formulation designed to detoxify and resolve blood stasis, potentially improving hepatic fibrosis and cirrhosis outcomes. Used for Hepatic fibrosis and cirrhosis (phase 3 development).

At a glance

Generic name	Jiedu Huayu Oral Prescription
Sponsor	Beijing Tiantan Hospital
Modality	Small molecule
Therapeutic area	Hepatology
Phase	Phase 3

Mechanism of action

This herbal oral prescription combines multiple botanical ingredients traditionally used in Chinese medicine to clear heat-toxins (jiedu) and invigorate blood circulation (huayu). The formulation is hypothesized to reduce hepatic inflammation, inhibit hepatic stellate cell activation, and promote resolution of fibrotic tissue remodeling in chronic liver disease. The mechanism reflects traditional Chinese medicine principles rather than a single molecular target.

Approved indications

Hepatic fibrosis and cirrhosis (phase 3 development)

Common side effects

No common side effects on file.

Key clinical trials

Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Jiedu Huayu Oral Prescription CI brief — competitive landscape report
Jiedu Huayu Oral Prescription updates RSS · CI watch RSS
Beijing Tiantan Hospital portfolio CI

Frequently asked questions about Jiedu Huayu Oral Prescription

What is Jiedu Huayu Oral Prescription?

Jiedu Huayu Oral Prescription is a Small molecule drug developed by Beijing Tiantan Hospital, indicated for Hepatic fibrosis and cirrhosis (phase 3 development).

How does Jiedu Huayu Oral Prescription work?

Jiedu Huayu Oral Prescription is a traditional Chinese medicine formulation designed to detoxify and resolve blood stasis, potentially improving hepatic fibrosis and cirrhosis outcomes.

What is Jiedu Huayu Oral Prescription used for?

Jiedu Huayu Oral Prescription is indicated for Hepatic fibrosis and cirrhosis (phase 3 development).

Who makes Jiedu Huayu Oral Prescription?

Jiedu Huayu Oral Prescription is developed by Beijing Tiantan Hospital (see full Beijing Tiantan Hospital pipeline at /company/beijing-tiantan-hospital).

What development phase is Jiedu Huayu Oral Prescription in?

Jiedu Huayu Oral Prescription is in Phase 3.

Manufacturer: Beijing Tiantan Hospital — full pipeline
Therapeutic area: All drugs in Hepatology
Indication: Drugs for Hepatic fibrosis and cirrhosis (phase 3 development)
Compare: Jiedu Huayu Oral Prescription vs similar drugs
Pricing: Jiedu Huayu Oral Prescription cost, discount & access